1424337-22-3

Upstream product

• 136918-14-4 phthalimide 
• 1424337-18-7 3-(5-(1,3-dioxoisoindolin-2-yl)pentyloxy)-4-methoxybenzaldehyde 
• 954-81-4 N-(5-bromopentyl)phthalimide 
• 111-24-0 1,5-dibromo-pentane 

Downstream Products

• 1424337-25-6 3-(5-aminopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide 
• 1424337-29-0 3-(5-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)pentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide 
• 1424337-11-0 C₂₇H₃₁Cl₂N₃O₆ 

Relevant academic research and scientific papers

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

A novel class of dual pharmacology bronchodilators targeting both β2-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better β2-adrenoceptor agonist activities (pEC50 = 8.47-9.20) than the reference compound salmeterol (pEC50 = 8.3) and good inhibitory activity on PDE4B2 (IC 50 = 0.235-1.093 μM).